f Therapeutic Potentials of Anesthetics

References

1. Chen M. Ma S. Liu H. Dong Y. Tang J. Ni Z. Tan Y. Duan C. Li H. Huang H. Li Y. Cao X. Lingle C.J. Yang Y. Hu H. Brain region–specific action of ketamine as a rapid antidepressant. Science 2024 385 6709 eado7010 10.1126/science.ado7010 39116252
   [Google Scholar]
2. Lucantonio F. Roeglin J. Li S. Lu J. Shi A. Czerpaniak K. Fiocchi F.R. Bontempi L. Shields B.C. Zarate C.A. Tadross M.R. Pignatelli M. Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens. Neuron 2025 113 9 1398 1412.e4 10.1016/j.neuron.2025.02.021 40112815
   [Google Scholar]
3. Ma S. Chen M. Jiang Y. Xiang X. Wang S. Wu Z. Li S. Cui Y. Wang J. Zhu Y. Zhang Y. Ma H. Duan S. Li H. Yang Y. Lingle C.J. Hu H. Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature 2023 622 7984 802 809 10.1038/s41586‑023‑06624‑1 37853123
   [Google Scholar]
4. Ma Z.Z. Guzikowski N.J. Kim J.W. Kavalali E.T. Monteggia L.M. Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity. Science 2025 388 6747 646 655 10.1126/science.abb6748 40339008
   [Google Scholar]
5. Wang S. Huang C. Wang M. Di L. Liu C. Hashimoto K. Yang C. Myelin repair as a novel mechanism for ketamine’s sustained antipressant effects. Curr. Neuropharmacol. 2025 23 8 943 955 10.2174/011570159X349856241213144902 39819542
   [Google Scholar]
6. Breault M.S. Orguc S. Kwon O. Kang G.H. Tseng B. Schreier D.R. Brown E.N. Anesthetics as treatments for depression: Clinical insights and underlying mechanisms. Annu. Rev. Neurosci. 2025 48 1 103 124 10.1146/annurev‑neuro‑112723‑062031 39971384
   [Google Scholar]
7. Brenna C.T.A. Goldstein B.I. Zarate C.A. Orser B.A. Repurposing general anesthetic drugs to treat depression: A new frontier for anesthesiologists in neuropsychiatric care. Anesthesiology 2024 141 2 222 237 10.1097/ALN.0000000000005037 38856663
   [Google Scholar]
8. Prendergast N.T. Tiberio P.J. Girard T.D. Treatment of delirium during critical illness. Annu. Rev. Med. 2022 73 1 407 421 10.1146/annurev‑med‑042220‑013015 34752706
   [Google Scholar]
9. Zhu X.N. Li J. Qiu G.L. Wang L. Lu C. Guo Y.G. Yang K.X. Cai F. Xu T. Yuan T.F. Hu J. Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter. Neuron 2023 111 10 1626 1636.e6 10.1016/j.neuron.2023.02.017 36917979
   [Google Scholar]
10. Deng M. Wang Y. Zheng B. Advances in the use of dexmedetomidine for postoperative cognitive dysfunction. Anesthesiol. Perioper Sci. 2024 2 4 38 10.1007/s44254‑024‑00078‑y
    [Google Scholar]
11. Gabrovic L. Chen X. Huang H. Zhao H. Non-anesthetic effects of anesthetics and organ protection. Curr. Neuropharmacol 2025 2025 10.2174/011570159X359884250714172718
    [Google Scholar]
12. Pan X. Xi Y. Liang P. Huang J. Therapeutic potential of anesthesiology for sleep disorders in the perioperative period. Curr. Neuropharmacol. 2025 23 10.2174/011570159X368375250611103614 40598736
    [Google Scholar]
13. Song, Xingrong; Cai, Hui Therapeutic values for general anesthetics: from developmental neurotoxicity to neurotherapeutic agents. Curr. Neuropharmacol
    [Google Scholar]
14. Leng Y. Teng Y. Liu J. Zou X. Ou M. Zhu T. Liang P. Zhou C. The modulatory effects of anesthetics and analgesics on neuro-physiological monitoring and underlying mechanisms. Curr. Neuropharmacol. 2025 23 10.2174/011570159X349119250127104107 39976041
    [Google Scholar]
15. Hu X. Luo R. Lei F. Li X. Luo Y. Li Q. Yi L. Zhang X. Polyak A. Tao Y. Jiang R. Therapeutic potential of dexmedetomidine in neuropsychiatric disorders: From the bench to the clinic. Curr. Neuropharmacol. 2025 23 8 929 942 10.2174/011570159X349530241123140415 39757645
    [Google Scholar]